NASDAQ:MLAB Mesa Laboratories (MLAB) Stock Forecast, Price & News $131.36 +3.13 (+2.44%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$127.53▼$132.2350-Day Range$128.23▼$184.3552-Week Range$114.21▼$216.43Volume63,584 shsAverage Volume48,988 shsMarket Capitalization$705.40 millionP/E Ratio821.05Dividend Yield0.49%Price Target$166.00 ProfileProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Mesa Laboratories MarketRank™ ForecastAnalyst RatingN/A0.00 Rating ScoreUpside/Downside26.4% Upside$166.00 Price TargetShort InterestBearish8.70% of Float Sold ShortDividend StrengthWeakBased on Four FactorsSustainabilityN/ANews Sentiment0.62Based on 2 Articles This WeekInsider TradingSelling Shares$1.02 M Sold Last QuarterProj. Earnings Growth55.11%From $5.97 to $9.26 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.73 out of 5 starsMedical Sector795th out of 983 stocksProcess Control Instruments Industry10th out of 11 stocks 2.0 Analyst's Opinion Price Target Upside/DownsideAccording to analysts' consensus price target of $166.00, Mesa Laboratories has a forecasted upside of 26.4% from its current price of $131.36.Amount of Analyst CoverageMesa Laboratories has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.70% of the float of Mesa Laboratories has been sold short.Short Interest Ratio / Days to CoverMesa Laboratories has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.Change versus previous monthShort interest in Mesa Laboratories has recently decreased by 4.31%, indicating that investor sentiment is improving. Previous Next 0.8 Dividend Strength Dividend YieldMesa Laboratories has a dividend yield of 0.49%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthMesa Laboratories does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Mesa Laboratories is 400.00%. Payout ratios above 75% are not desirable because they may not be sustainable.Dividend SustainabilityBased on earnings estimates, Mesa Laboratories will have a dividend payout ratio of 6.91% next year. This indicates that Mesa Laboratories will be able to sustain or increase its dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MLAB. Previous Next 1.5 News and Social Media Coverage News SentimentMesa Laboratories has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Mesa Laboratories this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 1 people have added Mesa Laboratories to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mesa Laboratories insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,018,145.00 in company stock.Percentage Held by InsidersOnly 5.50% of the stock of Mesa Laboratories is held by insiders.Percentage Held by Institutions93.00% of the stock of Mesa Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Mesa Laboratories are expected to grow by 55.11% in the coming year, from $5.97 to $9.26 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mesa Laboratories is 821.05, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 124.14.Price to Earnings Ratio vs. SectorThe P/E ratio of Mesa Laboratories is 821.05, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 86.18.Price to Book Value per Share RatioMesa Laboratories has a P/B Ratio of 1.79. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Mesa Laboratories (NASDAQ:MLAB) StockMesa Laboratories, Inc. engages in the design, manufacture, and market of instruments and disposable products utilized in healthcare, pharmaceutical, food and beverage, medical device, and petrochemical industries. It operates through the following segments: Sterilization and Disinfection Control, Instruments, Continuous Monitoring, and Biopharmaceutical Development. The Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators. The Instrument segment designs, manufactures, and markets control instruments and disposable products used in the healthcare, pharmaceutical, food and beverage, medical device, industrial hygiene, and environmental air sampling industries. The Biopharmaceutical Development segment develops and sells automated systems for protein analysis and peptide synthesis solutions. The Continuous Monitoring segment includes development of systems used to monitor various environmental parameters. The company was founded by Luke R. Schmieder on March 26, 1982 and is headquartered in Lakewood, CO.Read More Receive MLAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mesa Laboratories and its competitors with MarketBeat's FREE daily newsletter. Email Address MLAB Stock News HeadlinesMay 29, 2023 | americanbankingnews.comMesa Laboratories, Inc. (NASDAQ:MLAB) Declares $0.16 Quarterly DividendMay 25, 2023 | finanznachrichten.deMesa Laboratories, Inc.: Mesa Labs Announces Unaudited Fourth Quarter and Full Fiscal Year 2023 ResultsJune 3, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.May 25, 2023 | finance.yahoo.comMesa Labs (MLAB) Q4 Earnings and Revenues Miss EstimatesMay 25, 2023 | finance.yahoo.comMesa Labs Announces Unaudited Fourth Quarter and Full Fiscal Year 2023 ResultsMay 24, 2023 | msn.comMesa Laboratories's Earnings OutlookMay 23, 2023 | americanbankingnews.comMesa Laboratories (MLAB) to Release Quarterly Earnings on ThursdayMay 22, 2023 | finance.yahoo.comInvestor Optimism Abounds Mesa Laboratories, Inc. (NASDAQ:MLAB) But Growth Is LackingJune 3, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.May 2, 2023 | finance.yahoo.comMesa Laboratories (NASDAQ:MLAB) Is Reinvesting At Lower Rates Of ReturnApril 15, 2023 | americanbankingnews.comMesa Laboratories (NASDAQ:MLAB) Trading Down 2.4%April 5, 2023 | msn.comMesa Laboratories (MLAB) Declares $0.16 DividendApril 3, 2023 | finance.yahoo.comMesa Labs (MLAB) Stock Sinks As Market Gains: What You Should KnowApril 3, 2023 | finance.yahoo.comInvestors in Mesa Laboratories (NASDAQ:MLAB) have unfortunately lost 33% over the last yearMarch 29, 2023 | americanbankingnews.comJohn Sakys Sells 2,500 Shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) StockMarch 29, 2023 | americanbankingnews.comJohn Sakys Sells 2,128 Shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) StockMarch 13, 2023 | finance.yahoo.comMesa Laboratories, Inc. Reports Immaterial Financial Exposure to Silicon Valley Bank ClosureMarch 9, 2023 | finance.yahoo.comMesa Laboratories, Inc. to Announce Fourth Quarter and Full Fiscal Year 2023 Results on May 25, 2023February 27, 2023 | seekingalpha.comMesa Laboratories: Divisional Growth, Valuations Supportive Of HoldFebruary 21, 2023 | finance.yahoo.comA Look At The Fair Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)February 13, 2023 | finance.yahoo.comIs Mesa Labs (MLAB) a Solid Growth Stock? 3 Reasons to Think "Yes"February 13, 2023 | finance.yahoo.comMesa Labs Releases Environmental, Social, and Governance Program BrochureFebruary 10, 2023 | gurufocus.comShould Investors Worry About Mesa Laboratories Inc's Insider Sells?February 7, 2023 | msn.comMesa Laboratories's Return on Invested Capital InsightsFebruary 6, 2023 | finanznachrichten.deMesa Laboratories, Inc.: Mesa Labs Announces Third Quarter ResultsFebruary 6, 2023 | finance.yahoo.comMesa Labs (MLAB) Tops Q3 Earnings EstimatesFebruary 6, 2023 | seekingalpha.comMesa Laboratories Non-GAAP EPS of $2.35 beats by $0.77, revenue of $54.29M misses by $2.76MSee More Headlines MLAB Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MLAB Company Calendar Last Earnings5/31/2021Ex-Dividend for 3/15 Dividend2/27/2023Dividend Payable3/15/2023Ex-Dividend for 6/15 Dividend5/30/2023Today6/03/2023Dividend Payable6/15/2023Next Earnings (Estimated)8/03/2023Fiscal Year End3/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Process control instruments Sub-IndustryElectronic Equipment & Instruments SectorMedical Current SymbolNASDAQ:MLAB CUSIP59064R10 CIK724004 Webwww.mesalabs.com Phone(303) 987-8000Fax303-987-8989Employees506Year FoundedN/APrice Target and Rating Average Stock Price Forecast$166.00 High Stock Price Forecast$166.00 Low Stock Price Forecast$166.00 Forecasted Upside/Downside+26.4%Consensus RatingN/A Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)$0.16 Trailing P/E Ratio821.05 Forward P/E Ratio22.00 P/E GrowthN/ANet Income$930,000.00 Net Margins0.42% Pretax Margin-0.18% Return on Equity8.40% Return on Assets4.84% Debt Debt-to-Equity Ratio0.47 Current Ratio2.74 Quick Ratio1.93 Sales & Book Value Annual Sales$219.08 million Price / Sales3.22 Cash Flow$12.06 per share Price / Cash Flow10.89 Book Value$73.27 per share Price / Book1.79Miscellaneous Outstanding Shares5,370,000Free Float5,052,000Market Cap$705.40 million OptionableNot Optionable Beta0.74 Key ExecutivesJohn James SullivanChairmanGary M. OwensPresident, CEO, COO & DirectorJohn V. SakysCFO, Treasurer & Chief Accounting OfficerPeter JungVice President-Strategy & Corporate DevelopmentBrian ArchboldSenior Vice President-Continuous ImprovementKey CompetitorsArcturus TherapeuticsNASDAQ:ARCTArdelyxNASDAQ:ARDXAmneal PharmaceuticalsNYSE:AMRXLyell ImmunopharmaNASDAQ:LYELRAPT TherapeuticsNASDAQ:RAPTView All CompetitorsInsiders & InstitutionsAmeriprise Financial Inc.Sold 4,175 shares on 5/22/2023Ownership: 1.150%JPMorgan Chase & Co.Sold 1,044,058 shares on 5/18/2023Ownership: 0.360%New York State Common Retirement FundSold 806 shares on 5/18/2023Ownership: 0.060%Thrivent Financial for LutheransSold 166 shares on 5/17/2023Ownership: 0.093%Kayne Anderson Rudnick Investment Management LLCBought 83 shares on 5/16/2023Ownership: 2.686%View All Insider TransactionsView All Institutional Transactions MLAB Stock - Frequently Asked Questions What is Mesa Laboratories' stock price forecast for 2023? 0 equities research analysts have issued 12-month price objectives for Mesa Laboratories' shares. Their MLAB share price forecasts range from $166.00 to $166.00. On average, they predict the company's stock price to reach $166.00 in the next year. This suggests a possible upside of 26.4% from the stock's current price. View analysts price targets for MLAB or view top-rated stocks among Wall Street analysts. How have MLAB shares performed in 2023? Mesa Laboratories' stock was trading at $166.21 at the start of the year. Since then, MLAB shares have decreased by 21.0% and is now trading at $131.36. View the best growth stocks for 2023 here. When is Mesa Laboratories' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our MLAB earnings forecast. How were Mesa Laboratories' earnings last quarter? Mesa Laboratories, Inc. (NASDAQ:MLAB) released its quarterly earnings results on Monday, May, 31st. The medical instruments supplier reported $0.74 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.91 by $0.17. The medical instruments supplier had revenue of $37.96 million for the quarter, compared to analyst estimates of $34.92 million. Mesa Laboratories had a trailing twelve-month return on equity of 8.40% and a net margin of 0.42%. How often does Mesa Laboratories pay dividends? What is the dividend yield for Mesa Laboratories? Mesa Laboratories declared a quarterly dividend on Monday, April 3rd. Shareholders of record on Wednesday, May 31st will be paid a dividend of $0.16 per share on Thursday, June 15th. This represents a $0.64 annualized dividend and a dividend yield of 0.49%. The ex-dividend date is Tuesday, May 30th. Read our dividend analysis for MLAB. What ETFs hold Mesa Laboratories' stock? ETFs with the largest weight of Mesa Laboratories (NASDAQ:MLAB) stock in their portfolio include MFAM Small-Cap Growth ETF (MFMS), Motley Fool Small-Cap Growth ETF (TMFS), SPDR S&P Health Care Equipment ETF (XHE), Invesco S&P SmallCap Health Care ETF (PSCH), Principal Healthcare Innovators ETF (BTEC), iShares U.S. Medical Devices ETF (IHI), Is Mesa Laboratories a good dividend stock? Mesa Laboratories (NASDAQ:MLAB) pays an annual dividend of $0.64 per share and currently has a dividend yield of 0.49%. The dividend payout ratio is 400.03%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, MLAB will have a dividend payout ratio of 6.91% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for MLAB. What is Gary Owens' approval rating as Mesa Laboratories' CEO? 5 employees have rated Mesa Laboratories Chief Executive Officer Gary Owens on Glassdoor.com. Gary Owens has an approval rating of 51% among the company's employees. This puts Gary Owens in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Mesa Laboratories own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mesa Laboratories investors own include NVIDIA (NVDA), Verizon Communications (VZ), Intel (INTC), Alibaba Group (BABA), Altria Group (MO), Micron Technology (MU), Exxon Mobil (XOM), AbbVie (ABBV), Advanced Micro Devices (AMD) and Becton, Dickinson and (BDX). What is Mesa Laboratories' stock symbol? Mesa Laboratories trades on the NASDAQ under the ticker symbol "MLAB." Who are Mesa Laboratories' major shareholders? Mesa Laboratories' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (16.16%), Conestoga Capital Advisors LLC (10.81%), Ranger Investment Management L.P. (4.19%), State Street Corp (4.08%), Principal Financial Group Inc. (3.06%) and Royce & Associates LP (2.95%). Insiders that own company stock include Brian David Archbold, David M Kelly, Evan Guillemin, Gary M Owens, Gregory Dinoia, John Bradley Schmieder, John James Sullivan, John Sakys and Shannon Hall. View institutional ownership trends. How do I buy shares of Mesa Laboratories? Shares of MLAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Mesa Laboratories' stock price today? One share of MLAB stock can currently be purchased for approximately $131.36. How much money does Mesa Laboratories make? Mesa Laboratories (NASDAQ:MLAB) has a market capitalization of $705.40 million and generates $219.08 million in revenue each year. The medical instruments supplier earns $930,000.00 in net income (profit) each year or $0.16 on an earnings per share basis. How many employees does Mesa Laboratories have? The company employs 506 workers across the globe. How can I contact Mesa Laboratories? Mesa Laboratories' mailing address is 12100 W 6TH AVE, LAKEWOOD CO, 80228. The official website for the company is www.mesalabs.com. The medical instruments supplier can be reached via phone at (303) 987-8000, via email at investorrelations@mesalabs.com, or via fax at 303-987-8989. This page (NASDAQ:MLAB) was last updated on 6/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mesa Laboratories, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.